mRNA Epstein-Barr Virus Vaccine Candidate Launches Phase 1 Study

mRNA Epstein-Barr Virus Vaccine Candidate Launches Phase 1 Study

Source: 
Precision Vaccines
snippet: 

Massachusetts-based Moderna, Inc. today announced the first participant had been dosed in the Eclipse Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus (EBV) vaccine candidate.